Search

Sartorius Stedim Biotech.

Aperta

SettoreFinanza

215.4 -1.73

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

213.4

Massimo

221.8

Metriche Chiave

By Trading Economics

Entrata

-28M

64M

Vendite

-39M

706M

P/E

Media del settore

79.114

26.043

EPS

0.94

Margine di Profitto

9.097

Dipendenti

10,134

EBITDA

16M

218M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+6.5% upside

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

691M

21B

Apertura precedente

217.13

Chiusura precedente

215.4

Notizie sul Sentiment di mercato

By Acuity

25%

75%

51 / 525 Classifica in Finance

Punteggio Tecnico

By Trading Central

Fiducia

Bullish Evidence

Sartorius Stedim Biotech. Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

8 gen 2026, 23:08 UTC

Acquisizioni, Fusioni, Takeovers

Rio Tinto, Glencore in Talks to Form World's Biggest Miner -- 3rd Update

8 gen 2026, 21:39 UTC

Acquisizioni, Fusioni, Takeovers

Glencore, Rio Tinto Restart Merger Talks -- 2nd Update

8 gen 2026, 20:54 UTC

Acquisizioni, Fusioni, Takeovers

Glencore, Rio Tinto Restart Merger Talks -- Update

8 gen 2026, 20:44 UTC

Acquisizioni, Fusioni, Takeovers

Glencore, Rio Tinto Restart Merger Talks

8 gen 2026, 17:05 UTC

Acquisizioni, Fusioni, Takeovers

Chinese Anta Sports Products Offers to Buy Pinault Family's Stake in Puma, Reuters Says, Citing Unnamed Sources

8 gen 2026, 16:43 UTC

I principali Market Mover

Babcock & Wilcox Shares Rise on Siemens Deal for Data Center Project

8 gen 2026, 23:44 UTC

Discorsi di Mercato

Nikkei May Rise on Weaker Yen -- Market Talk

8 gen 2026, 23:37 UTC

Discorsi di Mercato

Gold Steady, Underpinned by Geopolitical Risks -- Market Talk

8 gen 2026, 22:42 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

8 gen 2026, 22:42 UTC

Discorsi di Mercato

RBA Still Battling a Troubling Inflation Outlook, Says TD -- Market Talk

8 gen 2026, 22:30 UTC

Acquisizioni, Fusioni, Takeovers

Glencore, Rio Tinto Confirm Early Merger Talks -- Barrons.com

8 gen 2026, 21:53 UTC

Utili

These Stocks Moved the Most Today: Lockheed, Northrop, Alphabet, Applied Digital, Bloom Energy, Neogen, and More -- Barrons.com

8 gen 2026, 21:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

8 gen 2026, 21:50 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

8 gen 2026, 21:10 UTC

Acquisizioni, Fusioni, Takeovers

Rio Tinto Says Current Expectation That Any Deal Would Involve Buying Glencore Via Scheme of Arrangement

8 gen 2026, 21:09 UTC

Discorsi di Mercato

Oil Rises As Trump Said to Back Russia Sanctions Bill -- Market Talk

8 gen 2026, 21:09 UTC

Acquisizioni, Fusioni, Takeovers

Rio Tinto Confirms in Talks With Glencore Over Possible Merger

8 gen 2026, 20:21 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Down Despite Inventory Draw -- Market Talk

8 gen 2026, 19:44 UTC

Discorsi di Mercato

Gold's Shine Masks Deep Drops in Canada Steel, Aluminum Exports -- Market Talk

8 gen 2026, 18:50 UTC

Discorsi di Mercato

Mexico's Industrial Production Seen Lower in November -- Market Talk

8 gen 2026, 17:48 UTC

Utili

These Stocks Are Moving the Most Today: Lockheed, Northrop, Alphabet, Applied Digital, Bloom Energy, Neogen, and More -- Barrons.com

8 gen 2026, 17:20 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

8 gen 2026, 17:20 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

8 gen 2026, 17:20 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

8 gen 2026, 17:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

8 gen 2026, 16:45 UTC

Discorsi di Mercato

Goldman Lifts 1H LME Copper Forecast -- Market Talk

8 gen 2026, 16:03 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

8 gen 2026, 16:03 UTC

Discorsi di Mercato

Currency Markets Could Be Underpricing Medium-Term Risks -- Market Talk

8 gen 2026, 16:02 UTC

Discorsi di Mercato

U.S. Natural Gas Inventories Fall As Expected -- Market Talk

8 gen 2026, 15:23 UTC

Acquisizioni, Fusioni, Takeovers

Paramount Defends Its Hostile Bid for Warner -- Update

Sartorius Stedim Biotech. Previsione

Obiettivo di Prezzo

By TipRanks

6.5% in crescita

Previsioni per 12 mesi

Media 237.5 EUR  6.5%

Alto 260 EUR

Basso 210 EUR

Basato su 8 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Sartorius Stedim Biotech. - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

8 ratings

6

Acquista

2

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

202.7 / 211.7Supporto e resistenza

A breve termine

Bullish Evidence

A termine intermedio

Strong Bullish Evidence

A lungo termine

Strong Bullish Evidence

Sentiment

By Acuity

51 / 525 Classifica in Finanza

Notizie sul Sentiment di mercato

Prove rialziste molto forti

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Sartorius Stedim Biotech.

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.
help-icon Live chat